- Title
- Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
- Creators
- Juan Pablo Alderuccio - University of MiamiRuss A Kuker - University of MiamiIsildinha M Reis - University of MiamiMuthiah Nachiappan - Sylvester Comprehensive Cancer CenterBrad S. Kahl - Washington University in St. LouisMehdi Hamadani - Medical College of WisconsinWeiyun Z. Ai - UCSF Helen Diller Family Comprehensive Cancer CenterJohn Radford - Manchester Academic Health Science CentreMelhem Solh - BMT GroupKirit M. Ardeshna - University College London Hospitals NHS Foundation TrustBrian T. Hess - Medical University of South CarolinaMatthew A. Lunning - University of Nebraska Medical CenterPier Luigi Zinzani - University of BolognaAnastasios Stathis - Institute of Oncology ResearchCarmelo Carlo-Stella - IRCCS Humanitas Research HospitalEric Yu - Adc TherapeuticsPaolo F Caimi - Cleveland ClinicDeukwoo Kwon - University of MiamiIzidore S. Lossos - Sylvester Comprehensive Cancer CenterFei Yang - Sylvester Comprehensive Cancer CenterCraig H. Moskowitz - University of Miami Health System
- Publication Details
- Blood, Vol.140(Supplement 1), pp.6650-6652
- Academic Unit
- UMMG Dept of Medicine - Hematology/Oncology; UMMG Department of Public Health Sciences Research; Miller School of Medicine; UMMG Department of Medicine; UMMG Department of Radiology; UMMG Dept of Radiation Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031785766802976
Journal article
Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
Blood, Vol.140(Supplement 1), pp.6650-6652
2022-11-15
Metrics
15 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites